Interaction of L2 with beta -Actin Directs Intracellular Transport of Papillomavirus and Infection*

Rongcun YangDagger , William H. Yutzy IVDagger , Raphael P. Viscidi§, and Richard B. S. RodenDagger ||

From the Departments of Dagger  Pathology, § Pediatrics, and  Gynecology and Obstetrics, The Johns Hopkins School of Medicine, Baltimore, Maryland 21205

Received for publication, August 23, 2002, and in revised form, January 23, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Viruses that replicate in the nucleus, including the primary causative agent of cervical cancer, human papillomavirus type 16 (HPV16), must first cross the cytoplasm. We compared the uptake of HPV16 virus-like particles (VLPs) either with or without the minor capsid protein L2. Whereas VLPs containing only the major capsid protein L1 were diffusely distributed within the cytoplasm even 6 h post-infection, VLPs comprising both L1 and L2 exhibited a radial distribution in the cytoplasm and accumulated in the perinuclear region of BPHE-1 cells within 2 h. L2 of HPV16 or bovine papillomavirus was shown to bind to a 43-kDa cellular protein that was subsequently identified as beta -actin by matrix-assisted laser desorption ionization time-of-flight analysis. A conserved domain comprising residues 25-45 of HPV16 L2 was sufficient for interaction with beta -actin. HPV16 L2 residues 25-45 fused to green fluorescent protein, but not green fluorescent protein alone, colocalized with actin and caused cell retraction and disruption of the microfilament network. Finally, wild-type L2, but not L2 with residues 25-45 deleted, facilitated HPV16 pseudovirion infection. Thus, binding of beta -actin by L2 residues 25-45 facilitates transport of HPV16 across the cytoplasm during infection, and blockade of this novel interaction may be useful for prophylaxis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Passive diffusion of molecules within the cytoplasm is limited by molecular crowding and does not provide targeting to a particular subcellular domain (1). Thus, many intracellular pathogens subvert existing transport mechanisms and cytoskeletal components, both to efficiently reach their site of replication and also for the exit of their progeny (2). The cytoskeleton is highly dynamic, and its role in locomotion is regulated by a plethora of actin- and tubulin-binding proteins, kinases, and phosphatases of multiple signaling cascades. Changes in tyrosine phosphorylation of actin regulatory proteins induce the condensation of actin "comet" tails behind endosomes (3), as well as the bacteria Listeria, Shigella, and Rickettsia (4) and viruses including vaccinia, baculovirus, and SV40, for propulsion through the cytoplasm (5, 6). Other viruses employ cellular motors such as dyneins and kinesins for transport along microtubules. A single virus type can employ several intracellular transport mechanisms. Indeed, vaccinia particles are driven along microtubules by kinesin, whereupon actin tails take over propulsion (7, 8).

Compelling epidemiologic and molecular virologic studies demonstrate that infection with an oncogenic type human papillomavirus (HPV),1 typified by HPV16, is a necessary cause of cervical cancer (9). In the absence of effective screening programs, cervical cancer is a leading cause of cancer death in women (10). Furthermore, oncogenic HPV infection is also strongly associated with vulval, anal, and penile cancers, some non-melanoma skin cancers, and esophageal and salivary cancers (11). An understanding of the infectious process is critical to rational development of approaches for prevention of HPV-related cancers. Although several cellular molecules, including heparan sulfate glycosaminoglycans (12), alpha 6 integrin (13), and CD16 (14), have been implicated as cell-surface receptors for papillomavirus, little else is known about cellular proteins that mediate cytoplasmic transport of papillomavirus and delivery of the viral genome to the nucleus.

The papillomavirus capsid comprises the major capsid protein L1 arranged as 72 pentamers, or capsomers, in a T=7d icosahedral surface lattice (15, 16) and a minor capsid protein, L2 (17), one molecule of which may be located at each vertex (18). Overexpression of L1 alone is sufficient to form empty capsids, termed virus-like particles (VLPs) (19). L1 VLPs bind to cell surfaces and compete with bovine papillomavirus type 1 (BPV1) infection in vitro (20). However, both L1 and L2 are necessary for efficient production of papillomavirus and infection (21-23). Recent studies by Kawana et al. (24, 25) suggest that residues 108-120 of L2 are displayed upon the virion exterior and bind to the cell surface, resulting in internalization. Furthermore, anti-L2 antiserum neutralizes papillomavirus without preventing virion binding to the cell surface (26). We recently demonstrated that L2 plays a critical role in infection, but is not required for interaction of papillomavirus particles with the cell surface (23). Taken together, the data suggest that L1 mediates the initial binding of virions to the cell surface, whereas L2 provides later functions critical for infection.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Preparation of Papillomavirus VLPs and L2-- VLPs containing L1 and L2, only L1, or L1 and L2 lacking residues 25-45 were generated by infection of Sf9 with recombinant baculoviruses and purified as previously reported (27). The HPV16 L2Delta 25-45 deletion mutant was prepared by two rounds of PCR using oligonucleotides CGCGGATCCATGCGACACAAACGTTCTGC and CCCATACTTCCATATTGTAACTGTTTGCATGTTTTATAAAG or TCCCCCCGGGCTAGGCAGCCAAAGAGAC and CTTTATAAAAACATGCAAACAGTTACAATATGGAAGTATGGG, followed by just the outside primers. The quantity and quality of VLP preparations were analyzed by SDS-PAGE and electron microscopy, respectively. His6-tagged BPV1 L2 fusion proteins were prepared as previously described (26). For generation of glutathione S-transferase (GST)-tagged L2-green fluorescent protein (GFP) fusion proteins, L2 oligonucleotides with EcoRI and SalI overhangs were directly synthesized (HPV16 L2-(13-31), AATTCGCATCGGCTACCCAACTTTATAAAACATGCAAACAGGCAGGTACATGTCCACCTGACGG and TCGACCGTCAGGTGGACATGTACCTGCCTGTTTGCATGTTTTATAAAGTTGGGTAGCCGATGCG; HPV16 L2-(25-45), AATTCGCAGGTACATGTCCACCTGACATTATACCTAAGGTTGAAGGCAAAACTATTGCTGAT CAAATAGG and TCGACCTATTTGATCAGCAATAGTTTTGCCTTCAACCTTAGGTATAATGTCAGGTGGACATGTACCTGCG; HPV16 L2-(61-81), AATTCGGAACAGGGTCGGGTACAGGCGGACGCACTGGGTATATTCCATTGGGAACAAGGCCTCCCACAGG and TCGACCTGTGGGAGGCCTTGTTCCCAATGGAATATACCCAGTGCGTCCGCCTGTACCCGACCCTGTTCCG; and HPV16 L2-(108-126), AATTCTTAGTGGAAGAAACTAGTTTTATTGATGCTGGTGCACCAACATCTGTACCTTCCATCGG and TCGACCGATGGAAGGTACAGATGTTGGTGCACCAGCATCAATAAAACTAGTTTCTTCCACTAAG) or amplified by PCR using HPV16 L2-(1-128) (primers GCAGAATTCATGCGACACAAACGTTCTGCA and GCAGGTCGACTGGGGGAATGGAAGGTAC) and HPV16 L2-(299-333) (primers GCAGAATTCACTGGCATTAGGTACAGT and GCAGGTCGACTTCTTCTGCAGGATCAATAGT). Expression of the recombinant GST-tagged proteins in Escherichia coli BL21 and their purification on a GSTrapTM FF column (Amersham Biosciences) were performed according to the manufacturer's instructions.

Metabolic Labeling and Immunoprecipitation-- Cells were grown overnight in Dulbecco's modified Eagle's medium and 10% fetal calf serum containing 35S-radiolabeled methionine and cysteine (0.2 mCi/ml) and harvested in ice-cold buffer A (10 mM HEPES (pH 7), 1 mM EDTA, 0.1 mM EGTA, 10 mM KCl, 1 mM dithiothreitol, and 20 mM n-octyl beta -D-glucopyranoside with Complete® protease inhibitor mixture (Roche Molecular Biochemicals)). The nuclei were removed by centrifugation at 12,000 × g for 15 min at 4 °C, and the lysate was precleared with 100 µl of protein G-Sepharose and 20 µg/ml isotypic control antibody for 2 h at 4 °C. After addition of His6- or GFP-tagged fusion protein, immunoprecipitation was performed with anti-His5 or anti-GFP monoclonal antibody, respectively, and protein G-Sepharose for 16 h at 4 °C with slow agitation. The immunoprecipitates were washed six times with ice-cold lysis buffer and resolved by 10% SDS-PAGE. After treating with 50% (v/v) methanol and 10% (v/v) acetic acid and then AmplifyTM (Amersham Biosciences) for 30 min, the gel was dried under vacuum at 60-80 °C, and the incorporated 35S was visualized by autoradiography.

43-kDa Protein Purification and Identification-- GST-HPV16 L2-(1-128)-GFP was bound to a GSTrap FF column, and detergent extracts of 109 SiHa cells in buffer A were passed over the column. After extensive washing, the column was eluted with 50 mM Tris-HCl and 10 mM reduced glutathione at pH 8.0. Eluates were analyzed by SDS-PAGE and silver staining. The 43-kDa protein band was excised and digested with TPCK-treated sequencing grade trypsin (Worthington) as previously described (28). The masses of the resulting peptides were measured by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) analysis on a Voyager DE STR apparatus (Applied Biosystems, Foster City, CA). Positive ion mass spectra were analyzed using Data Explorer (Version 3.5). Mass accuracy was better than 100 ppm. beta -Actin was identified by using the monoisotopic masses acquired from the 43-kDa protein to search the NCBI Non-redundant Database using the MS-Fit search engine on the Protein Prospector Web site.2

Flow Cytometric Analysis of L2-GFP Binding-- After fixation for 5 min in 3.7% paraformaldehyde and phosphate-buffered saline (PBS), cells were permeabilized with 1% (v/v) Triton X-100 for 20 min. The cells were incubated with the L2-GFP fusion protein for 1 h at room temperature, washed, and then analyzed by flow cytometry (FACScan, BD Biosciences).

Transfection-- The HPV16 L2-(25-45) fragment was subcloned between the EcoRI and SalI restriction sites of pEGFP-C2 (Clontech). The constructs were then transfected into COS-7 cells using LipofectAMINE 2000 (Invitrogen) according to the recommended protocol. Three days after transfection, the cells were stained with rhodamine-phalloidin (Molecular Probes, Inc.) and examined by confocal fluorescence microscopy (UltraView confocal imaging system, PerkinElmer Life Sciences).

Indirect Immunofluorescence, Rhodamine-Phalloidin Staining, and Confocal Microscopy-- BPHE-1 cells were incubated with VLPs for 1 h at 4 °C in Dulbecco's PBS and then washed with medium at 37 °C. At the time points indicated, the cells were washed with PBS, fixed with 3.7% formaldehyde solution for 10 min, permeabilized with 0.1% (v/v) Triton X-100 in PBS for 5 min, and blocked with PBS containing 1% bovine serum albumin for 30 min. Monoclonal antibody H16.V5 was used at 1:100 dilution for detection of HPV16 L1, and fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Sigma) was added at 5 µg/ml for 20 min at 4 °C. Actin was stained with rhodamine-phalloidin. Samples were examined by confocal fluorescence microscopy using a Nikon Eclipse TE 200 inverted microscope equipped with a ×40 plan fluor or ×60 or ×100 plan apochromatic objective lens with a corresponding 1-, 0.8-, or 0.45-µm optical z-slice. Twelve bit images were merged and analyzed with the UltraView acquisition software, RGB mode.

Electron Microscopy-- HPV16 VLPs were bound to BPHE-1 cells for 1 h at 4 °C. The cells were washed; shifted to 37 °C for 15 min; and then fixed in 2% glutaraldehyde, 0.05 M sodium cacodylate, and 3 mM CaCl2 (pH 7.4) for 30 min at room temperature with gentle rocking. After fixation in 0.5% OsO4 and 0.8% potassium ferrocyanide in buffer for 15 min on ice, the cells were dehydrated with a graded series of ethanol and embedded in Eponate 12 (Ted Pella, Inc.) overnight. Samples were treated with 0.15% tannic acid for 1 min, rinsed, and then stained en bloc in uranyl acetate for 2 h in the dark. The sections were cut and examined with a Phillips CM120 transmission electron microscope operating at 80 kV.

Generation and Infectivity of HPV16 Pseudovirions-- HPV16 pseudovirions were generated, and their infectivity was assayed as described previously (22). The HPV16 L2Delta 25-45 deletion mutant was prepared as described for the generation of HPV16 particles. The resulting DNA was inserted into the BamHI and XmaI restriction sites of pSFV4.2.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

L2 Facilitates Perinuclear Trafficking-- To further define the role of L2 in the infectious process, we compared the binding, uptake, and intracellular transport of HPV16 VLPs containing both L1 and L2 (L1/L2 VLPs) with VLPs comprising only L1 (L1 VLPs) (27) in the permissive cell line BPHE-1 (29). HPV16 VLPs were incubated with BPHE-1 cells for 1 h at 4 °C and visualized by indirect immunofluorescence. As we previously demonstrated (20), VLPs comprising L1 and L2 or only L1 bound to cell surfaces with a similar pattern and degree (data not shown). Upon shifting to 37 °C for 15 min to initiate synchronized uptake, the cells were fixed, sectioned, and examined by transmission electron microscopy. No differences were noted in the cellular ultrastructure of plasma membrane-associated L1 VLPs (Fig. 1, A1 and A2) or L1/L2 VLPs (B1 and B2) or their engulfment by invagination of the plasma membrane (A2 and B2). At 30 min and 1, 2, and 6 h after shifting the BPHE-1 cells to 37 °C, the VLPs were localized (Fig. 2) by indirect immunofluorescence using the HPV16 L1-specific, conformationally dependent, neutralizing monoclonal antibody H16.V5 (30, 31). Interestingly, L1/L2 VLPs aligned along distinct radial tracks across the cytoplasm and within ~2 h at 37 °C arrived in the perinuclear region (Fig. 2, A1-A3). However, L1 VLPs were not aligned along such radial tracks. Rather, L1 VLPs remained widely distributed throughout the whole cell and showed a less clear-cut tropism toward the nucleus during this 6-h time course (Fig. 2, B1-B3). These differences in the uptake of L1/L2 and L1 VLPs suggest that L2 contributes to the transport of virions across the cytoplasm.


View larger version (123K):
[in this window]
[in a new window]
 
Fig. 1.   Ultrastructural analysis of L1/L2 and L1 VLP uptake into BPHE-1 cells. HPV16 VLPs were bound to BPHE-1 cells for 1 h at 4 °C. The cells were washed; shifted to 37 °C for 15 min (A1, A2, B1, and B2) or 30 min (B3-B5); and then fixed in 2% glutaraldehyde, 0.05 M sodium cacodylate, and 3 mM CaCl2 (pH 7.4) for 30 min at room temperature with gentle rocking. After fixation in 0.5% OsO4 and 0.8% potassium ferrocyanide in buffer for 15 min on ice, the cells were dehydrated with a graded series of ethanol and embedded in Eponate 12 overnight. Samples were treated with 0.15% tannic acid for 1 min, rinsed, and then stained en bloc in uranyl acetate for 2 h in the dark. The sections were cut and examined with a Phillips CM120 transmission electron microscope operating at 80 kV. A1 and A2, binding and engulfment of L1 VLPs; B1 and B2, binding and engulfment of L1/L2 VLPs; B3, L1/L2 VLPs bound to the surface of BPHE-1 cells (arrow 1), particles within a vesicle that exhibits pinching (arrow 2), and particles free in the cytoplasm (arrow 3); B4, fine filaments radiating from L1/L2 VLPs in the cytoplasm; B5, a fine filament emanating from L1/L2 VLPs toward a microtubule (arrow 1) and a microtubule (arrow 2).


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 2.   L2 promotes rapid transport across the cytoplasm and radial distribution of VLPs. Subconfluent BPHE-1 cells were incubated with 10 µg of HPV16 VLPs comprising L1/L2 (A panels), L1 alone (B panels), or L1 and L2 lacking residues 25-45 (C panels) for 1 h at 4 °C and then shifted to 37 °C for various times. The cells were fixed at 30 min (A1-C1), 1 h (A2-C2), and 2 h (A3-C3), respectively, with 3.7% formaldehyde solution for 10 min, permeabilized with 0.1% (v/v) Triton X-100 in PBS for 5 min, and blocked with PBS containing 1% bovine serum albumin for 30 min. Murine monoclonal antibody H16.V5 was used at 1:100 dilution for detection of HPV16 L1, and fluorescein isothiocyanate-conjugated goat anti-mouse IgG (green) was added at 5 µg/ml for 20 min at 4 °C. Actin was stained with rhodamine-phalloidin (red). Samples were examined by confocal fluorescence microscopy (UltraView confocal imaging system). D, cytochalasin B at 10 µM depolymerizes actin and prevents the uptake of L1/L2 VLPs into cells; E, actins in a normal BPHE-1 cell; F, localization of beta -tubulin (red) and L1 VLPs (green) at 2 h after shifting to physiologic temperature.

Because the cytoskeleton provides a framework for intracellular transport and L1/L2 VLPs exhibited a radial distribution (Fig. 2, A1 and A2) during transit to the perinuclear region, we determined the subcellular localization of cytoskeletal components during VLP uptake. Furthermore, Liu et al. (32) observed an interaction between L1 and tubulin, as well as blockade of particle uptake by the microtubule-depolymerizing agent nocodazole. Thus, we examined the relative localization of HPV16 L1 VLPs and tubulin by immunofluorescent staining. However, limited overlap of L1 VLP and tubulin signals was noted 2 h after uptake (Fig. 2F). Cytochalasin B both disrupted the microfilament network by depolymerizing actin (Fig. 2, compare D and E) and inhibited uptake of HPV16 L1 (data not shown) and L1/L2 (Fig. 2D) VLPs, consistent with previous studies (33). Therefore, we compared the localization of actin (using rhodamine-phalloidin) and VLPs during their uptake. Upon their initial uptake, the VLPs colocalized with cortical actin at the periphery of the cell. At later time points, the radially distributed L1/L2 VLPs colocalized with actin filaments (Fig. 2A2), whereas little overlap was observed for L1 VLPs and actin (compare A and B panels). Thus, actin polymerization is critical early in VLP uptake, and the particles colocalize with actin microfilaments while traversing the cytoplasm. Although other viruses, including the structurally related SV40, induce the formation of actin comet tails (34), this phenomenon was not observed during HPV16 VLP uptake, suggesting a different mode of transport.

Residues 25-45 of L2 Bind beta -Actin-- BPV1 is frequently exploited in virologic studies because, unlike HPVs (35), BPV can be readily prepared in milligram quantities, and its infectivity can be readily assayed in vitro (36). To identify cellular "targeting molecule(s)" recognized by L2, we generated in E. coli six His6-tagged polypeptides spanning residues 1-88, 45-173, 130-257, 216-340, 300-425, and 384-469 that together encompass the entire open reading frame of BPV1 L2 (26). These polypeptides were each incubated with [35S]methionine/cysteine-radiolabeled SiHa cell lysates (data not shown) or HeLa cell lysates and immunoprecipitated with a monoclonal antibody specific for their tag. BPV1 L2 residues 1-88 co-immunoprecipitated with a cellular protein of ~43 kDa, whereas the other fragments, including the overlapping BPV1 L2 peptide comprising amino acids 45-173, did not (Fig. 3A). This implies that residues 1-45 of L2 mediate binding to a 43-kDa cellular protein.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   The conserved N terminus of BPV1 and HPV16 L2 binds to the 43-kDa cellular protein. A, detergent lysates of 35S-radiolabeled HeLa cells were subjected to centrifugation at 12,000 × g for 15 min at 4 °C and precleared with 100 µl of protein G-Sepharose and 20 µg/ml isotypic control (contr.) antibody for 2 h at 4 °C. After addition of His6-tagged BPV1 L2 fragments comprising the residues indicated, immunoprecipitation was performed with His5-specific monoclonal antibody and protein G-Sepharose for 16 h at 4 °C with slow agitation. The immunoprecipitates were washed six times with ice-cold lysis buffer and resolved by 10% SDS-PAGE and autoradiography. B, purified GST-GFP alone (GFP) or fused to HPV16 L2 residues 1-128 (1-128) was incubated with 35S-radiolabeled and precleared SiHa cell lysates and immunoprecipitated using monoclonal antibody to GFP or isotype-matched control antibody. C, coprecipitation was performed as described for B, but using GST-GFP fused to different regions of HPV16 L2. D, HeLa cell lysate in ice-cold buffer A was clarified by centrifugation at 16,000 × g for 30 min and passed over glutathione-Sepharose precoated with GST-GFP either alone or fused to HPV16 L2 residues 25-45, 1-128, or 299-333 or with GST fused to full-length HPV16 L2. After extensive washing, the bound proteins were eluted with 50 mM Tris-HCl and 10 mM reduced glutathione (pH 8.0) and analyzed by Western blotting with mouse anti-beta -actin monoclonal antibody (AC-15, Sigma). E, purified GST-GFP alone or fused to HPV16 L2 fragment 25-45 or control fragment 299-333 was incubated with purified rabbit muscle actin in PBS for 1 h and then passed through a GSTrap FF column. After extensive washing, the bound proteins were eluted and visualized by SDS-PAGE and Coomassie staining.

Unlike the C-terminal sequence, the first ~120 amino acids of L2 are well conserved among the >70 known papillomavirus genotypes. To examine whether the N-terminal domain of L2 derived from other papillomavirus genotypes is also able bind to this 43-kDa cellular protein, we next generated in E. coli a chimera comprising GST fused in-frame to amino acids 1-128 of HPV16 L2 and GFP to form GST-HPV16 L2-(1-128)-GFP. The purified fusion protein was incubated with [35S]methionine/cysteine-radiolabeled SiHa cell lysates and immunoprecipitated using a monoclonal antibody to GFP. The GST-HPV16 L2-(1-128)-GFP (but not GST-GFP) fusion protein also bound to the 43-kDa cellular protein (Fig. 3B), showing that this interaction is conserved in two evolutionarily distant papillomavirus types, BPV1 and HPV16. When testing smaller N-terminal subfragments of HPV16 L2, only residues 25-45 co-immunoprecipitated with the 43-kDa cellular protein from detergent lysates of radiolabeled SiHa cells (Fig. 3C), suggesting that this motif is sufficient for interaction.

To determine the distribution of the cellular protein that interacts with the HPV16 L2-GFP fusion protein, we examined, by confocal fluorescence microscopy (Fig. 4, A1.1-A1.4) and flow cytometry (A2.1-A2.4), the binding to detergent-permeabilized human cervical carcinoma-derived cell lines of GST-GFP chimeric proteins either with or without HPV16 L2 residues 1-128. Whereas the GST-GFP fusion protein failed to bind to SiHa cells, GFP fusion proteins containing either residues 1-128 or 25-45 of HPV16 L2 bound to a similar extent within the cytoplasm of the detergent-permeabilized SiHa cells (Fig. 4). To eliminate the possible effects of GST in the binding of the fusion protein to cells, the GST-HPV16 L2-GFP fusion proteins were digested with PreScission protease (Fig. 4B1, PreS.P) to release the GST tag (37). Thus, the binding to SiHa cells of PreScission protease-digested (Fig. 4B3.2) and undigested (Fig. 4B3.4) GST-HPV16 L2-(25-45)-GFP fusion protein was compared. L2-GFP (but not GFP alone) bound to SiHa cells to a similar extent either with or without GST, indicating that neither GST nor GFP mediates binding. Flow cytometric analysis showed that HPV16 L2 residues 1-128 bound to both HPV-positive cervical carcinoma-derived cell lines HeLa (data not shown) and SiHa (Fig. 4A2.2) to a similar extent as the HPV-negative human cervical carcinoma-derived cell line C33A (Fig. 4A2.4), indicating that HPV16 L2 binds to a cytoplasmic component that is not derived from papillomavirus.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 4.   Residues 25-45 of HPV16 L2 bind to a non-viral component of the cytoplasm. A, HPV16-positive (SiHa; A1.1, A1.2, A2.1, and A2.2) and HPV-negative (C33A; A1.3, A1.4, A2.3, and A2.4) cervical carcinoma-derived cell lines were washed with PBS, fixed with 3.7% paraformaldehyde, and then permeabilized with 1% (v/v) Triton X-100 for 20 min. The cells were incubated for 1 h at room temperature with purified fusion protein comprising GST-GFP alone (A1.1, A1.3, A2.1, and A2.3) or fused to residues 1-128 of HPV16 L2 (A1.2, A1.4, A2.2, and A2.4), washed, and examined by confocal fluorescence microscopy (A1 panels; scale bars = 10 µm) or flow cytometry (A2 panels). B1, GST-GFP fusion proteins containing various HPV16 L2 fragments (shown for residues 25-45) were affinity-purified, digested with PreScission protease (PreS.P), and analyzed by SDS-PAGE and Coomassie staining. B2.1 and B2.2, the binding of GFP alone and the HPV16 L2-(25-45)-GFP fragment, respectively, to SiHa cells was detected by laser scanning confocal microscopy. B3.1-B3.4, the binding of the HPV16 L2-(25-45)-GFP fragment to SiHa cells is independent of the GST tag. Shown are the results from flow cytometric analysis of the binding to SiHa cells of PreScission protease-digested (B3.1 and B3.2) or undigested (B3.3 and B3.4) GFP-GST fusion protein either lacking (B3.1 and B3.3) or including (B3.2 and B3.4) residues 25-45 of HPV16 L2.

To identity the 43-kDa cellular protein, a detergent lysate of SiHa cells was passed over a GST-HPV16 L2-(1-128)-GFP-coated column. After extensive washing, the proteins bound were eluted and visualized by SDS-PAGE and silver staining (data not shown). The 43-kDa protein band recovered was excised and subjected to in-gel trypsin digestion and MALDI-TOF analysis. This analysis resulted in the identification of 13 peptides whose protein sequences were all consistent with beta -actin (Fig. 5, A and B).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5.   Tryptic mass fingerprint identifies the 43-kDa band as beta -actin. A, the 43-kDa protein band that bound to residues 1-128 of HPV16 L2 was excised and digested with TPCK-treated sequencing grade trypsin as previously described (28). Masses of the resulting peptides were measured by MALDI-TOF analysis on a Voyager DE STR apparatus. Positive ion mass spectra were analyzed using Data Explorer (Version 3.5). Mass accuracy was better than 100 ppm. B, the predicted and measured peptide masses are listed. beta -Actin was identified by using the acquired monoisotopic masses to search the NCBI Non-redundant Database using the MS-Fit search engine on the Protein Prospector Web site (see Footnote 2).

Because peptides of L2 were used for the actin binding experiments, it is possible that the truncations resulted in exposure on a nonphysiologic cryptic epitope. To demonstrate interaction between full-length L2 and actin, a detergent lysate of HeLa cells was passed over glutathione-Sepharose beads precoated with GST fused to full-length HPV16 L2. The bound proteins were separated by electrophoresis and subjected to Western blot analysis using a mouse monoclonal antibody to beta -actin (Fig. 3D). Full-length HPV16 L2 and its fragments 1-128 and 25-45 bound to actin, whereas fragment 299-333 and the GFP control did not (Fig. 3D). Thus, binding to actin is a property of full-length L2.

It is unclear whether L2 binds directly to actin. Therefore, to address this question, purified GST-GFP fusion proteins containing HPV16 L2 residues 25-45 or, as a negative control, residues 299-333 were incubated for 1 h at ambient temperature with actin purified from rabbit muscle (A-2522, Sigma). Upon pull-down with glutathione-Sepharose, actin copurified with the GST-GFP fusion protein containing residues 25-45 (but not residues 299-333) of HPV16 L2 (Fig. 3E). This observation strongly supports the existence of a direct interaction between HPV16 L2 residues 25-45 and actin.

L2 Residues 25-45 Are Necessary for Efficient Transport to the Perinuclear Region and HPV16 Infection-- Studies in other viral systems suggest that interaction with actin can facilitate the intracellular transport of viral particles and infection. Therefore, to address the biologic significance of the putative actin-binding domain in HPV16 L2, we compared the uptake of HPV16 VLPs comprising wild-type L1 alone, L1 and L2, and L1 and L2 with residues 25-45 deleted (L1/L2Delta 25-45). Whereas wild-type HPV16 L1/L2 VLPs were rapidly transported to the perinuclear region along radial tracts (Fig. 2A1), L1/L2 VLPs lacking residues 25-45 failed to align along radial tracts in the cytoplasm and did not reach the perinuclear region during a 6-h time course (Fig. 2, C1-C3). Rather, L1/L2Delta 25-45 VLPs remained widely distributed throughout the cell as described for L1 VLPs (Fig. 2, B1-B3).

Because papillomavirus exhibits a high particle to infectivity ratio in vitro (22), it is possible that the uptake of HPV16 VLPs shown in Fig. 1 does not represent the true infectious pathway. Therefore, to examine the significance of this interaction between L2 and beta -actin to the infectious process, we generated HPV16 pseudovirions lacking the conserved beta -actin-binding domain, viz. residues 25-45 (Fig. 6A), and tested their infectivity using a previously described system. Briefly, the hamster fibroblast cell line BPHE-1 harbors 50-200 episomal copies of the bovine papillomavirus genome/cell (29), but it produces no virus because the L1 and L2 genes are not expressed. However, ectopic expression of HPV16 L1 and L2 in BPHE-1 cells via infection with recombinant defective Semliki Forest viruses results in the generation of infectious HPV16 pseudovirions containing the BPV genome within capsids formed of HPV16 L1 and L2 (22). Like native BPV1 virions, the infectivity of HPV16 {BPV1} pseudovirions can readily be quantified using the in vitro focal transformation of mouse C127 cells (36). HPV16 pseudovirions lacking residues 25-45 of L2 showed dramatically reduced infectivity (Fig. 6), suggesting that interaction between L2 and beta -actin indeed plays a critical role in the infectious process of papillomavirus.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   L2 residues 25-45 are required for efficient HPV16 pseudovirion infection. A, the putative actin-binding motif (residues 25-45 of HPV16 L2) is highly conserved among the different papillomavirus types. EEPV, European Elk Papillomavirus; RhPV, Rhesus papillomavirus. B, shown is the effect of the L2Delta 25-45 deletion mutation on infection of C127 cells by HPV16 pseudovirions. HPV16 pseudovirions were generated in BPHE-1 cells, and their infectivity was assayed as described previously (22). The presence of infectious HPV16 pseudovirions in extracts of BPHE-1 cells expressing wild-type HPV16 L1 and L2 (L1+L2), L1 and L2 lacking residues 25-45 (L1+L2(25+45)), or L1 alone was assessed using the focus forming assay in monolayers of C127 cells and compared with untreated control (Contr.) C127 cells. Mouse C127 cells were maintained for 3 weeks in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. The plates were stained with 0.5% (w/v) methylene blue and 0.25% (w/v) carbol fuchsin in methanol to highlight transformed foci for counting. C, foci counted in four experiments are plotted.

Cytoplasmic Overexpression of HPV16 L2 Residues 25-45 Disrupts the Actin Architecture-- Actin is one of most abundant proteins in eukaryotic cells, and its role as a primary determinant of cell shape, cytoplasmic structure, and locomotion is highly regulated by a plethora of binding proteins. Given the ability of L2 to bind to actin and the karyophilic nature of full-length L2, we hypothesized that an overabundance of L2 within the cytoplasm might induce changes in the cytoskeleton and cell morphology. To test this hypothesis, the fragment of HPV16 L2 encoding residues 25-45 was inserted 3' of the GFP gene in the mammalian expression vector pEGFP-C2 to form pEGFP-L2-(25-45). COS-7 cells were transfected with either pEGFP-C2 or pEGFP-L2-(25-45). Three days after transfection, equivalent expression of GFP alone and fused to HPV16 L2 residues 25-45 was confirmed by Western blot analysis with a monoclonal antibody to GFP (data not shown). The subcellular localization of actin (upon staining with rhodamine-phalloidin) and either GFP alone or fused to HPV16 L2 residues 25-45 was examined by confocal fluorescence microscopy. Transient expression of GFP fused to HPV16 L2 residues 25-45 within the cytoplasm of COS-7 cells induced a dramatic retraction of transfected cells from the culture surface (Fig. 7B1). In contrast, expression of GFP alone in the transfected cells did not noticeably influence cell morphology (Fig. 7A1) compared with the parental untransfected cells (data not shown). Interestingly, staining revealed apparent reorganization of filamentous actin into cytoplasmic bundles, which colocalized with the GFP fusion proteins containing HPV16 L2 residues 25-45 (Fig. 7, B1-B4). GFP did not significantly colocalize with actin staining even in dividing cells that had retracted from the culture dish (Fig. 7, A1-A4). Thus, cytoplasmic overexpression of the actin-binding domain of HPV16 L2 is sufficient to induce retraction of COS-7 cells and actin reorganization.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7.   Expression of HPV16 L2 residues 25-45 in COS-7 cells alters cell morphology and actin structure. COS-7 cells in two-well chamber slides were transfected using LipofectAMINE 2000 with 1 µg of plasmid vector pEGFP encoding GFP (A panels) or pEGFP-L2-(25-45) encoding GFP fused to HPV16 L2 residues 25-45 (B panels). After 3 days, the cells were stained with rhodamine-phalloidin and analyzed by confocal microscopy. A1 and B1, phase-contrast light microscopy; A2 and B2, GFP fluorescence; A3 and B3, actin stained with rhodamine-phalloidin; A4 and B4, overlays of fluorescence channels.

Furthermore, we examined, by transmission electron microscopy, sections of BPHE-1 cells 30 min after addition of HPV16 VLPs for the association of intracellular L1/L2 or L1 particles with actin microfilament-like structures. Fig. 1B3 shows surface-bound HPV16 L1/L2 VLPs, large groups of particles within vesicles, and individual particles free in the cytoplasm. The majority of 50 HPV16 L1/L2 VLPs present in the cytoplasm were associated with fine filamentous structures whose width is consistent with that of actin microfilaments. HPV16 L1/L2 VLPs occasionally formed "star-like" structures (Fig. 1B4) with fine filaments radiating from the capsid surface or a halo around the particle in the dense cortical actin (data not shown), suggestive of actin rearrangement. Fine filaments (Fig. 1B5, arrow 1) that seemed to link HPV16 L1/L2 particles to microtubules (arrow 2) were also found. However, we did not observe such structures in association with 50 L1 VLPs free in the cytoplasm of BPHE-1 cells (data not shown).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

During the infectious process, an intracellular pathogen hijacks the normal cellular function of its receptor molecules for transportation to its site of replication. Thus, study of such infectious pathways can both enhance our understanding of normal cellular transport as well as identify targets for intervention. Although intracellular pathogens use diverse primary and secondary receptors to gain entry to the cell, the mechanisms employed for intracellular transport are more restricted. For example, microorganisms as diverse as Listeria, Shigella, Rickettsia, vaccinia, and SV40 employ different receptors to gain entry to a cell, but a similar mode of intracellular transport (6, 34). However, despite their structural similarity to SV40 (18), the papillomaviruses use a distinct cell-surface receptor and entry pathway, about which little is known. Indeed, three different surface molecules (12-14) have been proposed to bind to the major capsid protein L1 and to function as the primary receptor for papillomavirus. Papillomavirus L1 pseudovirions prepared in vitro are infectious, although significantly less so than those containing L2 (38-40). We have provided genetic evidence that L2 also plays a critical role during papillomavirus infection, but after the initial binding of the particle to the cell surface (23). By virtue of its ability to bind to and enter cells, L2 was recently proposed to bind to a secondary viral receptor and to facilitate uptake (24). The inability of L1 VLPs to enter the nucleus (41) and the importance of the DNA-binding and karyophilic domains of L2 to the infectious process suggest that interaction of L2 with the viral genome may play a key role in its delivery to the nucleus (23, 42).

The high local protein concentration (as high as 300 mg/ml), organelles, and the cytoskeleton contribute to the molecular crowding within a cell that restricts the free diffusion of molecules of >500 kDa (1). Because the papillomavirus capsid is 55 nm in diameter and >2000 kDa, its free diffusion within the cell will be extremely slow (15). During infection, the virus needs to rapidly traffic to the nucleus, the site of viral replication, rather than to other organelles such as lysosomes. To efficiently transport particles across the cytoplasm during infection, residues 25-45 of HPV16 L2 bind to beta -actin, and this interaction influences microfilament structure. However, understanding the mechanism of locomotion requires further investigation.

The high degree of sequence conservation of the L2 motif (Fig. 6A) and the ability of both BPV1 and HPV16 L2 to bind actin suggest that this interaction is common to other papillomavirus genotypes and therefore may represent a useful target for the development of pan-papillomavirus-preventative treatments. Indeed, antibody to L2 (but not L1) neutralizes diverse papillomavirus genotypes, suggesting that a conserved functional domain of L2 is displayed on the capsid surface (25, 43). Furthermore, L2-specific neutralizing antibodies predominantly recognize its N terminus and do not prevent virions from binding to the cell surface (26), suggesting that neutralization may occur by a blockade of virion uptake or intracellular transport.

Several pathogens have independently evolved mechanisms to harness the power of actin polymerization to get into and out of cells (34). Indeed, the entry of a wide variety of viruses, including papillomavirus, human immunodeficiency virus, vaccinia, Autographa californica M nucleopolyhedrovirus, adenovirus type 2, and echoviruses, is dependent upon actin polymerization as demonstrated by blockade with the inhibitor cytochalasin D (44). However, this does not necessarily reflect a direct interaction between the virus and actin because actin function is necessary for receptor-mediated endocytosis and many other cellular processes.

A. californica M nucleopolyhedrovirus induces the formation of thick actin cables that frequently project toward the nucleus. These actin cables are transiently formed in association with the viral nucleocapsids prior to viral gene expression and concomitantly with nucleocapsid transport to the nucleus (45). Two virus-encoded capsid proteins, p39 and p78/83, in A. californica M nucleopolyhedrovirus were found to bind to actin directly and therefore could be involved in the observed acceleration of actin polymerization by viral actin-binding proteins (46). It is unclear how this effect relates to the changes in actin structure produced by overexpression of L2 residues 25-45 within the cytoplasm because neither papillomavirus L1/L2 VLPs nor L2 induces such actin cables.

Both endosomes and diverse pathogens are able to recruit host cytoskeletal factors to induce the polymerization of actin filaments from their surface into a structure known as a comet tail for intracellular propulsion (34). However, the presence of L2 or L1/L2 VLPs during infection did not promote the formation of such actin comet tails, suggesting that interaction of L2 with beta -actin facilitates particle transport by another mechanism.

Actin is an ATPase, and ATP hydrolysis affects the kinetics of polymerization (47). In vivo, actin polymerization is a highly regulated process controlled both by ATP binding and hydrolysis and by the action of a number of actin-binding proteins that initiate, cleave, cross-link, stabilize, or destabilize the filaments (48). Actin comet tails result from a depolymerization of filamentous actin and re-polymerization behind the particle (34). Interestingly, overexpression of the beta -actin-binding motif comprising residues 25-45 of HPV16 L2 in the cytoplasm was associated with the redistribution of actin in COS-7 cells and altered cell morphology. This is consistent with a functional interaction between L2 and actin in vivo that orchestrates the intracellular motility of papillomavirus during infection.

In addition to promoting uptake, the actin cytoskeleton facilitates egress of vaccinia from infected cells (8, 34). The spread of vaccinia is enhanced by actin tail formation that is triggered via tyrosine phosphorylation of A36R. Herpesvirus type 1 VP22 exploits microfilaments to promote intercellular spreading (49). Furthermore, interaction of the Black Creek Canal virus N protein with actin microfilaments is required for virion morphogenesis and release, but not infection (50). However, papillomavirus accumulates in microcrystalline arrays within the nucleus of productively infected cells, and there is currently no evidence for such an egress pathway mediated by L2-actin interaction.

    ACKNOWLEDGEMENTS

We thank T.-C. Wu (The Johns Hopkins University) and Andrew Lewis (Food and Drug Administration) for donating cell lines; Neil D. Christensen (Pennsylvania State University) for antibody H16.V5; Robert N. Cole for assistance in protein identification; the Mass Spectrometry Facility of The Johns Hopkins School of Medicine; Mike Delannoy (Microscopy Facility, The Johns Hopkins School of Medicine) for expert confocal and electron microscopy; Hung Chien-Fu and Lin Ken-Yu for discussion on molecular biotechnology; Liang-Mei He for technical assistance; and Drs. T.-C. Wu and Douglas Robinson (The Johns Hopkins University) and John T. Schiller and Douglas R. Lowy (National Cancer Institute) for providing critiques during the preparation of this manuscript.

    FOOTNOTES

* This work was supported by Grants AI48203 and CA83706 from the National Institutes of Health the Cancer Research Institute, and by American Cancer Society Grant RSG MBC-103111 (to R. B. S. R.). The work performed at the Mass Spectrometry Facility of The Johns Hopkins School of Medicine was supported by National Center for Research Resources Shared Instrumentation Grant 1S10-RR14702 and the Johns Hopkins Fund for Medical Discovery.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Dept. of Pathology, The Johns Hopkins School of Medicine, Ross 512B, 720 Rutland Ave., Baltimore, MD 21205. Tel.: 410-502-5161; Fax: 443-287-4295; E-mail: roden@jhmi.edu.

Published, JBC Papers in Press, January 30, 2003, DOI 10.1074/jbc.M208691200

2 Available at prospector.ucsf.edu.

    ABBREVIATIONS

The abbreviations used are: HPV, human papillomavirus; VLP, virus-like particle; BPV, bovine papillomavirus; GST, glutathione S-transferase; GFP, green fluorescent protein; TPCK, L-1-tosylamido-2-phenylethyl chloromethyl ketone; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Luby-Phelps, K. (2000) Int. Rev. Cytol. 192, 189-221[Medline] [Order article via Infotrieve]
2. Sodeik, B. (2000) Trends Microbiol. 8, 465-472[CrossRef][Medline] [Order article via Infotrieve]
3. Taunton, J., Rowning, B. A., Coughlin, M. L., Wu, M., Moon, R. T., Mitchison, T. J., and Larabell, C. A. (2000) J. Cell Biol. 148, 519-530[Abstract/Free Full Text]
4. Dramsi, S., and Cossart, P. (1998) Annu. Rev. Cell Dev. Biol. 14, 137-166[CrossRef][Medline] [Order article via Infotrieve]
5. Cudmore, S., Reckmann, I., and Way, M. (1997) Trends Microbiol. 5, 142-148[CrossRef][Medline] [Order article via Infotrieve]
6. Pelkmans, L., Puntener, D., and Helenius, A. (2002) Science 296, 535-539[Abstract/Free Full Text]
7. Rietdorf, J., Ploubidou, A., Reckmann, I., Holmstrom, A., Frischknecht, F., Zettl, M., Zimmermann, T., and Way, M. (2001) Nat. Cell Biol. 3, 992-1000[CrossRef][Medline] [Order article via Infotrieve]
8. Moss, B., and Ward, B. M. (2001) Nat. Cell Biol. 3, E245-E246[CrossRef][Medline] [Order article via Infotrieve]
9. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J., and Muñoz, N. (1999) J. Pathol. 189, 12-19[CrossRef][Medline] [Order article via Infotrieve]
10. Pisani, P., Parkin, D. M., Bray, F., and Ferlay, J. (1999) Int. J. Cancer 83, 18-29[Medline] [Order article via Infotrieve]
11. zur Hausen, H. (2002) Nat. Rev. Cancer 2, 342-350[CrossRef][Medline] [Order article via Infotrieve]
12. Joyce, J. G., Tung, J. S., Przysiecki, C. T., Cook, J. C., Lehman, E. D., Sands, J. A., Jansen, K. U., and Keller, P. M. (1999) J. Biol. Chem. 274, 5810-5822[Abstract/Free Full Text]
13. Evander, M., Frazer, I. H., Payne, E., Qi, Y. M., Hengst, K., and McMillan, N. A. (1997) J. Virol. 71, 2449-2456[Abstract]
14. Da Silva, D. M., Velders, M. P., Nieland, J. D., Schiller, J. T., Nickoloff, B. J., and Kast, W. M. (2001) Int. Immunol. 13, 633-641[Abstract/Free Full Text]
15. Baker, T. S., Newcomb, W. W., Olson, N. H., Cowsert, L. M., Olson, C., and Brown, J. C. (1991) Biophys. J. 60, 1445-1456[Abstract]
16. Hagensee, M. E., Olson, N. H., Baker, T. S., and Galloway, D. A. (1994) J. Virol. 68, 4503-4505[Abstract]
17. Doorbar, J., and Gallimore, P. H. (1987) J. Virol. 61, 2793-2799[Medline] [Order article via Infotrieve]
18. Trus, B. L., Roden, R. B., Greenstone, H. L., Vrhel, M., Schiller, J. T., and Booy, F. P. (1997) Nat. Struct. Biol. 4, 413-420[Medline] [Order article via Infotrieve]
19. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., and Schiller, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 12180-12184[Abstract]
20. Roden, R. B., Kirnbauer, R., Jenson, A. B., Lowy, D. R., and Schiller, J. T. (1994) J. Virol. 68, 7260-7266[Abstract]
21. Zhou, J., Stenzel, D. J., Sun, X. Y., and Frazer, I. H. (1993) J. Gen. Virol. 74, 763-768[Abstract]
22. Roden, R. B., Greenstone, H. L., Kirnbauer, R., Booy, F. P., Jessie, J., Lowy, D. R., and Schiller, J. T. (1996) J. Virol. 70, 5875-5883[Abstract]
23. Roden, R. B., Day, P. M., Bronzo, B. K., Yutzy, W. H., IV, Yang, Y., Lowy, D. R., and Schiller, J. T. (2001) J. Virol. 75, 10493-10497[Abstract/Free Full Text]W. H.
24. Kawana, Y., Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., and Kanda, T. (2001) J. Virol. 75, 2331-2336[Abstract/Free Full Text]
25. Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., and Kanda, T. (1999) J. Virol. 73, 6188-6190[Abstract/Free Full Text]
26. Roden, R. B., Weissinger, E. M., Henderson, D. W., Booy, F., Kirnbauer, R., Mushinski, J. F., Lowy, D. R., and Schiller, J. T. (1994) J. Virol. 68, 7570-7574[Abstract]
27. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D. R., and Schiller, J. T. (1993) J. Virol. 67, 6929-6936[Abstract]
28. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996) Anal. Chem. 68, 850-858[CrossRef][Medline] [Order article via Infotrieve]
29. Zhang, Y. L., Lewis, A., Jr., Wade-Glass, M., and Schlegel, R. (1987) J. Virol. 61, 2924-2928[Medline] [Order article via Infotrieve]
30. Christensen, N. D., Dillner, J., Eklund, C., Carter, J. J., Wipf, G. C., Reed, C. A., Cladel, N. M., and Galloway, D. A. (1996) Virology 223, 174-184[CrossRef][Medline] [Order article via Infotrieve]
31. Roden, R. B., Armstrong, A., Haderer, P., Christensen, N. D., Hubbert, N. L., Lowy, D. R., Schiller, J. T., and Kirnbauer, R. (1997) J. Virol. 71, 6247-6252[Abstract]
32. Liu, W. J., Qi, Y. M., Zhao, K. N., Liu, Y. H., Liu, X. S., and Frazer, I. H. (2001) Virology 282, 237-244[CrossRef][Medline] [Order article via Infotrieve]
33. Zhou, J., Gissmann, L., Zentgraf, H., Muller, H., Picken, M., and Muller, M. (1995) Virology 214, 167-176[CrossRef][Medline] [Order article via Infotrieve]
34. Frischknecht, F., and Way, M. (2001) Trends Cell Biol. 11, 30-38[CrossRef][Medline] [Order article via Infotrieve]
35. Meyers, C., Frattini, M. G., Hudson, J. B., and Laimins, L. A. (1992) Science 257, 971-973[Medline] [Order article via Infotrieve]
36. Dvoretzky, I., Shober, R., Chattopadhyay, S. K., and Lowy, D. R. (1980) Virology 103, 369-375[Medline] [Order article via Infotrieve]
37. Cordingley, M. G., Callahan, P. L., Sardana, V. V., Garsky, V. M., and Colonno, R. J. (1990) J. Biol. Chem. 265, 9062-9065[Abstract/Free Full Text]
38. Touze, A., and Coursaget, P. (1998) Nucleic Acids Res. 26, 1317-1323[Abstract/Free Full Text]
39. Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., and Kanda, T. (1998) J. Virol. 72, 10298-10300[Abstract/Free Full Text]
40. Unckell, F., Streeck, R. E., and Sapp, M. (1997) J. Virol. 71, 2934-2939[Abstract]
41. Merle, E., Rose, R. C., LeRoux, L., and Moroianu, J. (1999) J. Cell. Biochem. 74, 628-637[CrossRef][Medline] [Order article via Infotrieve]
42. Zhou, J., Sun, X. Y., Louis, K., and Frazer, I. H. (1994) J. Virol. 68, 619-625[Abstract]
43. Roden, R. B., Yutzy, W. H., IV, Fallon, R., Inglis, S., Lowy, D. R., and Schiller, J. T. (2000) Virology 270, 254-257[CrossRef][Medline] [Order article via Infotrieve]W. I.
44. Ploubidou, A., and Way, M. (2001) Curr. Opin. Cell Biol. 13, 97-105[CrossRef][Medline] [Order article via Infotrieve]
45. Charlton, C. A., and Volkman, L. E. (1993) Virology 197, 245-254[CrossRef][Medline] [Order article via Infotrieve]
46. Lanier, L. M., and Volkman, L. E. (1998) Virology 243, 167-177[CrossRef][Medline] [Order article via Infotrieve]
47. Korn, E. D., Carlier, M. F., and Pantaloni, D. (1987) Science 238, 638-644[Medline] [Order article via Infotrieve]
48. Schmidt, A., and Hall, M. N. (1998) Annu. Rev. Cell Dev. Biol. 14, 305-338[CrossRef][Medline] [Order article via Infotrieve]
49. Elliott, G., and O'Hare, P. (1997) Cell 88, 223-233[Medline] [Order article via Infotrieve]
50. Ravkov, E. V., Nichol, S. T., Peters, C. J., and Compans, R. W. (1998) J. Virol. 72, 2865-2870[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.